TrialCancer research and treatment2016

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.

Tak Yun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.